CYTOKINETICS, INCORPORATED Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYTOKINETICS, INCORPORATED stock issued during period, value, conversion of units for the quarter ending 2023-09-30 was -$43.40M.
- CYTOKINETICS, INCORPORATED stock issued during period, value, conversion of units for the quarter ending 2023-06-30 was $76.30M.
- CYTOKINETICS, INCORPORATED stock issued during period, value, conversion of units for the quarter ending 2023-03-31 was $372.00M.
- CYTOKINETICS, INCORPORATED stock issued during period, value, conversion of units for the quarter ending 2022-12-31 was -$27.80M.
- CYTOKINETICS, INCORPORATED stock issued during period, value, conversion of units for fiscal 2022 was $484.40M.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2023-09-30 | -$43.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $377.10M derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | $76.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | |
| 2023-03-31 | $372.00M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | -$27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $484.40M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |